These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 22681244)

  • 61. Is on-demand treatment effective in patients with severe haemophilia?
    Aznar JA; Marco A; Jiménez-Yuste V; Fernández-Fontecha E; Pérez R; Soto I; Parra R; Moreno M; Mingot ME; Moret A;
    Haemophilia; 2012 Sep; 18(5):738-42. PubMed ID: 22537601
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.
    Leissinger C; Gringeri A; Antmen B; Berntorp E; Biasoli C; Carpenter S; Cortesi P; Jo H; Kavakli K; Lassila R; Morfini M; Négrier C; Rocino A; Schramm W; Serban M; Uscatescu MV; Windyga J; Zülfikar B; Mantovani L
    N Engl J Med; 2011 Nov; 365(18):1684-92. PubMed ID: 22047559
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B.
    Monahan PE; Liesner R; Sullivan ST; Ramirez ME; Kelly P; Roth DA
    Haemophilia; 2010 May; 16(3):460-8. PubMed ID: 20059559
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Haemophilia A and haemophilia B. Are there relevant clinical differences?].
    Klamroth R; Orlovic M; Kubicek-Hofman C; Gottstein S
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S26-7. PubMed ID: 21042678
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
    Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
    Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.
    Fischer K; Astermark J; van der Bom JG; Ljung R; Berntorp E; Grobbee DE; van den Berg HM
    Haemophilia; 2002 Nov; 8(6):753-60. PubMed ID: 12410643
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
    Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
    Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Haemophilia care in Europe: the ESCHQoL study.
    Schramm W; Gringeri A; Ljung R; Berger K; Crispin A; Bullinger M; Giangrande PL; Von Mackensen S; Mantovani LG; Nemes L; Serban M;
    Haemophilia; 2012 Sep; 18(5):729-37. PubMed ID: 22639833
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis.
    Olivieri M; Kurnik K; Pfluger T; Bidlingmaier C
    Haemophilia; 2012 May; 18(3):369-74. PubMed ID: 22032268
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
    Valentino LA
    Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects.
    Valentino LA; Rusen L; Elezovic I; Smith LM; Korth-Bradley JM; Rendo P
    Haemophilia; 2014 May; 20(3):398-406. PubMed ID: 24418368
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Methods for individualising factor VIII dosing in prophylaxis.
    Ar MC; Vaide I; Berntorp E; Björkman S
    Eur J Haematol Suppl; 2014 Aug; 76():16-20. PubMed ID: 24957103
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Unresolved issues in prophylaxis.
    Brown SA; Aledort LM; Astermark J; Berntorp E; van den Berg M; Blanchette V; Donfield S; Gringeri A; Hilgartner M; Kulkarni R; Leissinger C; Negrier C; Nuss R; Petterson H; Petrini P; Poulios N; Schramm W;
    Haemophilia; 2002 Nov; 8(6):817-21. PubMed ID: 12410654
    [No Abstract]   [Full Text] [Related]  

  • 74. Secondary prophylaxis in adolescent and adult haemophiliacs.
    Tagliaferri A; Di Perna C; Rivolta GF
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s17-20. PubMed ID: 19105505
    [TBL] [Abstract][Full Text] [Related]  

  • 75. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations.
    Perry D; Berntorp E; Tait C; Dolan G; Holme PA; Laffan M; Lassila R; Mumford A; Pasi J; Wilde J; Will A; Yee TT
    Haemophilia; 2010 Jan; 16(1):80-9. PubMed ID: 19780845
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
    Hua B; Lian X; Li K; Lee A; Poon MC; Zhao Y
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
    Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The orthopaedic status of severe haemophiliacs in Spain.
    Aznar JA; Magallón M; Querol F; Gorina E; Tusell JM
    Haemophilia; 2000 May; 6(3):170-6. PubMed ID: 10792475
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prophylaxis in the haemophilia population.
    Blanchette VS
    Haemophilia; 2010 Jul; 16 Suppl 5():181-8. PubMed ID: 20590879
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A.
    Fischer K; Lewandowski D; Janssen MP
    Haemophilia; 2016 Sep; 22(5):e375-82. PubMed ID: 27353496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.